Brucellosis Vaccines Market, valued at USD 10.8 million in 2024, is projected to increase from USD 11.2 million in 2025 to USD 14.1 million by 2031, expanding at a moderate yet essential CAGR of 4.0% during the forecast period. As brucellosis continues to pose a major challenge to livestock health, veterinary services, food safety, and agricultural economies worldwide, vaccines remain the most effective intervention for prevention and control.
Claim a Free Insight Sample https://www.24lifesciences.com/download-sample/6607/brucellosis-vaccines-market
Demand for brucellosis vaccines is increasing as governments, veterinary institutions, and livestock farms intensify disease management programs across endemic as well as at-risk regions. The market’s growth is also driven by rising global livestock populations, economic losses linked to brucellosis infection, and expanding adoption of scientifically validated vaccination programs under international animal health guidelines.
Market Highlights
By Type
- S19 Vaccine
- RB51 Vaccine Strain
The S19 vaccine continues to be widely used due to its long history of efficacy in cattle, while the RB51 strain is increasingly adopted in regions prioritizing differentiation of infected from vaccinated animals (DIVA) capabilities. Both vaccine types remain central to national eradication strategies.
By Application
- Cattle
- Sheep
- Goats
- Others
Cattle represent the leading application segment, as brucellosis remains highly prevalent in bovine populations across many developing economies. Vaccination demand is also rising among goats and sheep, particularly in regions with significant small-ruminant agriculture.
By End User
- Government Vaccination Programs
- Private Veterinary Practices
- Large-Scale Livestock Farms
Government vaccination programs dominate the market, driven by large-scale, publicly funded initiatives aimed at controlling or eliminating brucellosis in endemic regions. Large-scale farms and private veterinary practices increasingly adopt structured vaccination strategies to reduce productivity losses and improve herd health.
By Vaccine Strain Characteristics
- Live Attenuated Vaccines
- Marker Vaccines
- Killed/Inactivated Vaccines
Live attenuated vaccines remain the most commonly utilized due to cost-effectiveness and high protective response. Meanwhile, marker vaccines and inactivated formulations are gaining attention for use in regions requiring greater traceability, safety, and compatibility with advanced diagnostics.
By Program Objective
- Control in Endemic Areas
- Eradication Campaigns
- Prevention in Free Regions
Control programs in endemic regions represent the highest share of the market. However, eradication campaigns and prevention efforts in officially brucellosis-free countries play an increasing role in shaping global demand for advanced vaccine types.
Claim a Free Insight Sample https://www.24lifesciences.com/download-sample/6607/brucellosis-vaccines-market
Emerging Trends Shaping the Healthcare Market
The Brucellosis Vaccines Market is witnessing modernization influenced by broader trends in healthcare, veterinary medicine, and life sciences. The integration of digital herd health platforms, AI-powered disease surveillance, and precision livestock farming tools is improving vaccination outcomes and enhancing early detection of outbreaks.
Furthermore, advancements in molecular diagnostics support greater compatibility between vaccines and surveillance programs. As sustainability becomes a priority, vaccine manufacturers are adopting greener production methods, improved cold-chain technologies, and eco-responsible packaging solutions.
These innovations are expected to accelerate disease control efforts, strengthen livestock productivity, and enhance the global brucellosis eradication agenda through 2032.
Regional Analysis
North America
North America remains a key region for brucellosis control, characterized by strict regulatory frameworks, extensive surveillance systems, and active vaccination initiatives. The U.S. continues to emphasize vaccination among cattle in high-risk states.
Europe
Europe maintains mostly brucellosis-free status but continues investing in prevention programs, especially in Southern and Eastern European regions. Strong veterinary infrastructure and government-backed monitoring programs support regional growth.
Asia-Pacific
Asia-Pacific represents one of the largest and fastest-growing markets due to high livestock density, significant disease burden, and the implementation of aggressive national vaccination programs. China, India, and Pakistan remain priority areas for widespread vaccination deployment.
Latin America & Africa
Both regions experience substantial brucellosis prevalence, driving large-scale demand for cost-effective vaccines. Government-led vaccination efforts, combined with support from international animal health organizations, drive steady market expansion.
Key Players & Competitive Landscape
The Brucellosis Vaccines Market is characterized by strong participation from global and regional veterinary biologics manufacturers. Industry players focus on expanding product portfolios, increasing production capacity, and enhancing strain efficacy through R&D.
Key companies profiled include:
- Jinyu
- Colorado Serum
- Boehringer Ingelheim
- Biogenesis-Bago
- Vetal Company
- CZ Veterinaria
- SYVA Laboratorios
- Indian Immunologicals
- Qilu
- Tecnovax
- Hester Biosciences
- Zoetis
- Onderstepoort Biological
- Instituto Rosenbusch
- Ceva Sante Animale
- Calier & Biologicos Laverlam
- Biovet
These companies compete through new vaccine development, supply chain expansion, regional partnerships, and technology-driven quality improvements.
Explore the Full Market Report https://www.24lifesciences.com/brucellosis-vaccines-market-6607
Forecast Overview
With a projected 4.0% CAGR through 2031, the Brucellosis Vaccines Market is expected to witness steady expansion. Continued focus on livestock productivity, rising awareness of zoonotic disease risks, and increasing emphasis on large-scale disease control programs will shape long-term demand.
As global strategies move toward eradication and prevention, vaccine adoption will remain central to improving animal health, ensuring food safety, and protecting agricultural economies worldwide
Explore our related reports
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: www.24lifesciences.com
Follow us on LinkedIn: www.linkedin.com/company/lifesciences24
- Single-Domain Heavy Chain Antibody Market - 2026-01-23
- Qianlie Antong Capsules Market - 2026-01-23
- Veterinary Amitraz Solution Market - 2026-01-23